RBCC: Survey Shows Teen Substance Abuse Falling, But Much Work Remains
HENDERSON, Nev.–(BUSINESS WIRE)–Rainbow Coral Corp. (OTCQB: RBCC)
is hailing a recent nationwide survey that shows substance abuse and
addiction among American teens has dropped, but the company says a lot
of hard work still lies ahead before the current crisis can be
considered over.
According to the recently
released Monitoring the Future (MTF) survey, young people
have decreased their use of many addictive substances, including
prescription opioid painkillers, alcohol, cigarettes and synthetic
cannabinoids (also known as synthetic marijuana). Use of prescription
opioids has sunk to its lowest level in 12 years, with 4.4 percent of
high school seniors reporting non-medical use, down from a 10.5 percent
in 2003.
“This is heartening news,” said RBCC CEO Kimberly Palmer. “It shows the
continued effort against opioid and alcohol addiction is having a
measurable and positive effect among teens. However, a lot of work
remains ahead and more needs to be done across all age groups. The
addiction crisis hasn’t gone away, despite this encouraging survey. This
is why we are heavily focused on that segment still battling alcohol and
opioid addiction – the adult population. And that’s why we are
continuing our work towards developing affordable treatment options for
those in need.”
The MTF survey, conducted annually by the University of Michigan,
measures drug use and attitudes among U.S. eighth, 10th, and 12th
graders.
Through its biotech subsidiary, Rainbow Biosciences, RBCC markets and
develops new medical and research technology innovations to compete
alongside companies such as Biogen Idec Inc. (BIIB),
Abbott Laboratories (ABT)
and Amgen Inc. (AMGN).
For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow
Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (RBCC).
The Company continually seeks out new partnerships with biotechnology
developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business
initiatives, please visit www.RainbowBioSciences.com.
For investment information and performance data on the Company, please
visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995: This news release contains forward-looking information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements that include the words “believes,”
“expects,” “anticipate” or similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, performance or achievements
of the Company to differ materially from those expressed or implied by
such forward-looking statements. In addition, description of anyone’s
past success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
Contacts
Rainbow Coral Corp.
Kimberly Palmer, 702-940-2345
President
and CEO
info@rainbowcoral.com
